To determine the efficacy and safety of risperidone for people with autism spectrum disorder& to study benefits of low dosage Risperidone in Autism

1. Risperidone in
Autism
Paper by Dr Kalpana Shekhawat 10/5/2011
Ruptech Educational India
To determine the efficacy and safety of risperidone for people with autism spectrum disorder&
to study benefits of low dosage Risperidone in Autism.

2. Objectives
To determine the efficacy and safety and tolerability of risperidone for people with autism
spectrum disorder& to study benefits of low dosage Risperidone in Autism.
Risperidone is a drug used in Psychiatric Medicine to treat cases of Schizophrenia, a form of
insanity. It acts on certain specific receptors on the brain that help to modify the behavior of
persons so afflicted.
Exact cause of Autism is not known but is believed to be multi factorial, with a strong genetic
influence.
There is a 60-90% concordance rate for monozygotic twins and a 0% concordance rate for di
zygotic twins. The genetic component of Autism is heterogeneous attributed to as many as
100 genes and genetic abnormalities in Autism have been identified in mitochondrial genes
and in all chromosomes except 14 and 20. It is believed that multiple genes interact with
varied environmental causes to produce the disorders, and that the causative genes may vary
from one population to another. Because of the complex heterogeneity and the variable
behavioral phenotype of Autism, linkage studies have not identified specific chromosomal
regions that are universally believed to harbor the genes causing it is initiated by at least 6 to
7 major genes and about 3 to 4 times that number of minor genes, causing a wide variety of
medical pathologies. One of those genes that may have something to do with the presence of
the HOXA1 gene coupled with the presence of mercury in the body. The metal gets
incorporated into the neural proteins to cause their dysfunction. This causes the
characteristic abnormal dissociated behavior patterns seen in children with Autism Spectrum
disorder.
Limitations:
Limited resources were available therefore a very small control group.
Exclusion criteria:
Children with known allergy to Risperidone
Liver & Kidney disorder
Juvenile diabetes
Inclusion Criteria:
Age 5-16 years
Only diagnosed autistics by a Pediatric Neurologist.
Material Required:
Syp Risinia (prescribed by their pediatrician)

3. Sample Size:
Planned 60 children, reduced to 4 children (2girls and 2boys) due to limited resources available.
ABSTRACT
Background:
Autistic children presents with psychiatric symptoms, pharmacotherapy is sometimes used to
ameliorate target behaviors. The behaviors include hyper activity, tantrums, and physical
aggression, self-injurious behavior, stereotypies, and anxiety symptoms, especially obsessive-
compulsive behaviors. The older neuroleptics were limited in their usefulness because of
their tendency to produce extrapyramidal symptoms and tardive dyskinesia. Open-label trials
of atypical neuroleptics (risperidone, olanzapine) have shown effectiveness in treating these
behaviors, and in some instances, have also improved social relatedness.
Naltrexone, an opiate antagonist was also originally touted as useful, especially for self-
injurious behavior, but its utility has not yet been proven. Clomipramine, a tricyclic
antidepressant that inhibits serotonin reuptake, has demonstrated usefulness in reducing
compulsions and stereotypies in autistic children. However, it does lower the seizure
threshold, can cause agranulocytosis, and has cardio toxic and behavior toxicity effects. Other
medications used to treat psychiatric symptoms in autistic children include stimulants,
selective serotonin reuptake inhibitors (SSRIs), and clonidine. The SSRIs, in particular, appear
to be somewhat effective in diminishing hyperactive, agitated, and obsessive-compulsive
behaviors although there have not yet been sufficient, controlled studies regarding their
utility.
Autistic spectrum disorder encompasses a wide variety of behavioral and communicative
problems. Both the core features and non-core features of autism have been targeted in a
variety of therapies. Atypical antipsychotic medications, including risperidone, have been used
for symptom and behavior improvement and have shown beneficial outcomes, particularly in
certain aspects of the disorder. However, given the nature of the condition presenting in young
patients, the risks of these potentially long term therapies must be weighed against the
benefits.
Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors,
have advantages over traditional antipsychotic medications in the treatment of adults with
schizophrenia and may be beneficial in children with autistic disorder who have serious
behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic
agents in children are limited.
Risperidone:

4. DRUG CLASS AND MECHANISM:
Risperidone is an atypical antipsychotic drug that is used for treating schizophrenia, bipolar
mania and autism. Other atypical antipsychotic drugs include Olanzapine (Zyprexa), Quetiapine
(Seroquel), Ziprasidone (Geodon), Aripiprazole (Abilify) and paliperidone (Invega). Atypical
antipsychotics differ from typical antipsychotics due to the lesser degree of extrapyramidal
(movement) side effects and constipation.
The mechanism of action of risperidone is like other anti-psychotics, risperidone affects the way
the brain works by interfering with communication among the brain's nerves. Nerves
communicate with each other by making and releasing chemicals called neurotransmitters. The
neurotransmitters travel to other nearby nerves where they attach to receptors on the nerves.
The attachment of the neurotransmitters either stimulates or inhibits the function of the
nearby nerves. Risperidone blocks several of the receptors on nerves including dopamine type
2, serotonin type 2, and alpha 2 adrenergic receptors. It is believed that many psychotic
illnesses are caused by abnormal communication among nerves in the brain and that by altering
communication through neurotransmitters, risperidone can alter the psychotic state.
Risperidone was approved by the FDA in December, 1993.
PRESCRIPTION: Yes
PREPARATIONS: Tablets: 1, 2, 3, and 4 mg. Suspension: 1 mg/ml. Orally disintegrating tablets:
1, 2, 3, and 4 mg.
STORAGE: Tablets should be kept at room temperature, 15-25 C (59-77 F).
PRESCRIBED FOR:
Risperidone is used to treat schizophrenia, bipolar mania [as a sole therapy or combination
therapy with lithium (Eskalith, Lithobid) or valproate (Depakene, Depacon) Clinical studies
involving small numbers of patients have shown some benefit in using risperidone for stuttering
and Tourette syndrome (non FDA-approved uses). Another non-FDA approved use of
risperidone is for obsessive-compulsive disorders.
DOSING:

5. Risperidone can be prescribed once or twice daily. Initial dosing is generally 2 mg/day. Dose
increases can occur in increments of 1-2 mg/day, as tolerated, to a recommended dose of 4-8
mg/day. In children, risperidone should be initiated at 0.5 mg once daily, and can be increased
in increments of 0.5 or 1 mg/day, as tolerated, to a recommended dose of 2.5 mg/day.
Risperidone can be given with or without meals. The recommended dose of Risperdal Consta is
25 mg injected into the deltoid or gluteal muscle every two weeks. Patients who have never
received risperidone are started on oral risperidone in order to evaluate tolerability. Patients
then may be transitioned to Risperdal Consta if oral risperidone is tolerated
DRUG INTERACTIONS: Risperidone may interfere with elimination by the kidneys of clozapine
(Clozaril), a different type of antipsychotic medication, causing increased levels of clozapine in
the blood. This could increase the risk of side effects with clozapine.
Serotonin reuptake inhibitors such as paroxetine(Paxil), Sertraline (Zoloft), and fluoxetine
(Prozac) when taken with risperidone causes the metabolism (breakdown) of risperidone by the
liver to be inhibited, which in turn causes elevated blood levels of risperidone, and may
increase the risk of adverse reactions.
Antifungal drugs such as fluconazole (Diflucan), itraconazole (Sporanox), and ketoconazole
(Nizoral) when taken with risperidone cause the metabolism (breakdown) of risperidone by the
liver to be inhibited, which in turn causes elevated blood levels and may increase the risk of
adverse reactions.
PREGNANCY: There are no adequate studies of risperidone in pregnant women. Some
unwanted effects have been reported in animal studies. Risperidone can be used in pregnancy
if the physician feels that the benefits outweigh the potential but unknown risks.
NURSING MOTHERS: Risperidone is excreted in human breast milk. Women receiving
risperidone should not breastfeed.
ADVERSE EFFECTS: The most commonly adverse effects associated with risperidone are extra
pyramidal effects (sudden, often jerky, involuntary motions of the head, neck, arms, body, or
eyes), dizziness, hyperactivity, tiredness, abdominal pain, fatigue, fever and nausea.
Risperidone may cause a condition called orthostatic hypotension during the early phase of
treatment (the first week or two). Patients who develop orthostatic hypotension have a drop in
their blood pressure when they rise from a lying position and may become dizzy or even lose
consciousness.
Studies involving risperidone suggest an increased risk of hyperglycemia-related adverse
reactions as seen in diabetes. Although there is no clear link between risperidone and diabetes,
patients should be tested during treatment for elevated blood sugars. Additionally, persons
with risk factors for diabetes, including obesity or a family history of diabetes, should have their
fasting levels of blood sugar tested before starting treatment and periodically throughout

6. treatment to detect the onset of diabetes. Any patient developing symptoms that suggest
diabetes during treatment should be tested for diabetes.
USES: Risperidone is used to treat certain mental/mood disorders (such as schizophrenia, manic
phase of bipolar disorder, occasionally irritability associated with autistic disorder). This
medication can help us to think clearly and function in daily life. This is a psychiatric medication
(antipsychotic-type) that works by helping to restore the balance of certain natural substances
in the brain (neurotransmitters).This medication may also be used in combination with other
medication to treat depression.
Autism the problem and Epidemiology
The autism spectrum, also called autism spectrum disorders (ASD) or autism spectrum
conditions (ASC), with the adjective autistic sometimes replacing the noun autism, is a
spectrum of psychological conditions characterized by widespread abnormalities of social
interactions and communication, as well as restricted interests and repetitive behavior.
Autism forms the core of the autism spectrum disorders. Asperger syndrome is closest to
autism. People with Asperger syndrome have no significant delay in language development
PDD-NOS is diagnosed when the criteria are not met for a more specific disorder. Some sources
also include Rett syndrome and childhood disintegrative disorder which share several signs with
autism but may have unrelated causes; other sources combine ASD with these two conditions
into the pervasive developmental disorders.
Autism characteristics
The defining characteristics of autism spectrum disorders are qualitative impairments of social
communication and interaction, along with restricted and repetitive activities and interests.
Individual symptoms occur in the general population and appear not to associate highly,
without a sharp line separating pathological severity from common traits other aspects of ASD,
such as atypical eating, are also common but are not essential for diagnosis; they can affect the
individual or the family.
An estimated 0.5% to 10% of individuals with ASD show unusual abilities, ranging from splinter
skills such as the memorization of trivia to the extraordinarily rare talents of prodigious autistic
savants
Making and maintaining friendships often proves to be difficult for children with autism. For
them, the quality of friendships, not the number of friends, predicts how lonely they are,

7. despite the common belief that they prefer to be alone. Being on the autism spectrum does not
keep children from understanding race and gender stereotypes in a society; like normal
children they can learn aspects of stereotypical behavior by observing their parents' actions.
Autism therapies
The main goals of treatment are to lessen associated deficits and family distress, and to
increase quality of life and functional independence. No single treatment is best and treatment
is typically modified to the child's needs. rigorous, sustained special education programs and
behavior therapy early in life can help children acquire self-care, social, and job skills. Available
approaches include applied behavior analysis (ABA), developmental models, structured
teaching, speech and language therapy, social skills therapy, and occupational therapy ABA
therapy has a strong research base but it maybe limited by diagnostic severity and IQ.
In a recent study by Russo et al., researchers at Albert Einstein College of Medicine of Yeshiva
University have provided new evidence that, children with autism spectrum disorders (ASD)
process sensory information including sound, touch and vision differently to typically
developing children. This research provides support for decades of clinical and anecdotal
observations by occupational therapists practicing sensory integration therapy that individuals
with ASD have difficulty coping with multiple sources of sensory information. These findings
offer an opportunity for occupational therapists to develop objective measures to facilitate
more empirical evaluation and understanding of sensory processing disorders and sensory
integration therapy
Epidemiology of autism
The prevalence rate of all pervasive developmental disorders appears to be 58.7 per 10000
children. This prevalence rate includes Autism (22/10000), Asperger syndrome (11/10000),
Pervasive developmental disorder not otherwise specified (24.8/10000) and child disintegrative
disorder (0.9/10000).this is consistent with previous research that identified all pervasive
development disorders as (60/10000).this incidence of diagnosis of autism may have increased.
there is evidence that increased in the number of children identified with autism is likely
related to changes in the definition of and diagnostic criteria for autism, as well as
improvements in the recognition of autism at younger ages. An increase in the availability of
diagnostic services, treatment facilities, professionals trained in childhood developmental
disorders has greatly increased the capacity of the healthcare system to identify and treat
children with autistic spectrum disorder at younger age.
Methods:

8. Random trail of risperidone in 4 children diagnosed with ASD as compared with placebo for the
treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious
behavior in children 5 to 16 years old. The primary outcome measures were the score on the
Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global
Impressions - Improvement (CGI-I) scale at eight weeks, data were recorded.
Dosage: Risinia syrup 1mg bi daily
Procedure: In this study 4 children were identified, who were already on risperidone in dosage
(1mg bidaily) prescribed by their pediatricians. Each child was assessed for severe tantrum,
aggression, self injurious behavior etc, primary outcome measures were the scores on the
irritability subscale of the Aberrant behavior checklist and the rating on the Clinical Global
Impression-Improvement(CGI-I) scale at 8 weeks.
Report
Study result of effect of Risperidone in children with Autism
Time period – 8 weeks, 10th Dec 10 to 4th Feb 11
Dose of medicine-1mg/BID as prescribed by their pediatricians.
Age groups-5-8yrs
Total no. of Age group Boys Girls Risperidone Placebo
children given given
4 5-8yrs 2 2 2 2
Outcome of Therapy
Out come Scale earlier Scale with Scale with
measures Risperidone Placebo
Irritability score 4 2 4
Clinical Global 4 3 4
Impression
Improvement scale
Weight gain 0 4 1
Increased Appetite 0 3 0
Fatigue 1 4 1.5-2

9. Drowsiness 0 3 1
Dizziness 0 2 0
Drooling 0 0 0
*Criteria’s measured at a scale of 1-5
Adverse events in 2 children with Autism who responded to Risperidone in an 8 weeks
trial.
Number of children
Adverse Event moderate
or severe event
Moderate Severe
Nasal congestion 2 0
Appetite increase 2 0
Coughing 0 0
Anxiety 0 0
Difficulty falling asleep 0 0
Fever 0 0
Skin irritation 0 0
Vomiting 0 0
Accidental injury 0 0
Constipation 0 0
Drowsiness/sedation 2 0
Enuresis 0 0
Headache 0 0
Hyper salivation 0 0
Sore throat 0 0
Depression 0 0
Diarrhea 0 0
Difficulty urinating 0 0

10. Dyskinesia 0 0
Earache 0 0
Restlessness/agitation 0 0
Sinus condition 0 0
Stomach /abdominal discomfort 0 0
Tiredness/fatigue 2 0
Tremor 0 0
Weight gain 2 0
Muscle rigidity 0 0
Other 0 0
Clinical Global Impression (CGI) Improvement Ratings for 2 children with Autism, who
responded to Risperidone in 8 weeks trial:
Rating Week 0 Week 4 Week 8
Very much improved 0 0 1
Much improved 0 0 1
Minimally improved 0 2 0
No change 2 0 0
Worse 0 0 0
(much worse) 0 0 0
Total 2 2 2
Discussion

11. Risperidone may be well-tolerated and effective treatment for up to 6 months for children with
autism complicated by tantrums, aggression, and self-injury. As measured by the primary
indices of response, the CGI improvement scale and the Aberrant Behavior Checklist irritability
subscale, improvements associated with risperidone administration were maintained with very
good tolerability. Furthermore, gradual substitution of placebo for risperidone was associated
with a greater return of aggression, temper outbursts, and self-injurious behavior than in the
subjects who continued to receive risperidone in the discontinuation phase. Risperidone may
be an efficacious treatment for short- and intermediate-term management of serious
behavioral problems in children with autism.
As in our study of short-term risperidone efficacy risperidone was also associated with
continued maintenance of improvements on the Aberrant Behavior Checklist subscales for
hyperactivity, stereotypic behavior, and lethargy/social withdrawal.
The largest extended study of neuroleptic treatment for autistic disorder was the examination
of the effects of haloperidol over a 6-month period. In that study 60 children treated with a
mean dose of 1.23 mg/day of haloperidol were classified as "good responders." After 6 months
of treatment, 33 (63%) of 52 subjects were rated as "much improved." Autism factor ratings
derived from the Children’s Psychiatric Rating Scale obtained on entry and at 6 months showed
an average decline of 23% from baseline. Upon abrupt withdrawal of haloperidol, only 14% of
the children were rated as much worse and 50% showed at least mild deterioration.
In an open-label prospective study of risperidone for 11 children with autistic disorder, Zuddas
et al. noted that 10 of the 11 showed enduring improvement over the 12-month observation
period. Another open trial of risperidone enrolled 22 subjects with autistic disorder. Of these,
15 subjects showed significant improvement at a mean dose of 1.2 mg/day for up to 7 months
of treatment. Additional published observations include positive responses maintained over a
4-month period in responders and improvement maintained during a 2-year treatment history
in two adults with autistic disorder It should be noted that few earlier studies defined specific
entry criteria for aggression or disruptive behavior, but, taken together, the available accounts
suggest that risperidone’s benefit for aggression, severe tantrums, and self-injury
accompanying autistic disorder persisted over these intermediate treatment periods (6–12
months), although additional long-term treatment data focusing on managing severe and
challenging behaviors are clearly needed.
A key clinical question concerns the length of continued treatment with risperidone for this
clinical indication. The return of aggression, tantrums, and agitation was there in the placebo
group as in the subjects who continued to take risperidone. 1 of 2 children in the placebo group
did not relapse during the 2-month discontinuation period, demonstrating some degree of
variability in outcome. It is conceivable that more gradual drug tapering may have moderated
the observed relapse in the risperidone group or that dose reduction, rather than complete
medication discontinuation, may have been sufficient to maintain treatment gains. It is also
conceivable that concomitant behavioral treatment reinforcing replacement behaviors could
protect against relapse following risperidone withdrawal. Nevertheless, the high rate of relapse

12. observed in our study suggests caution when withdrawal of effective treatment for these target
symptoms is considered. At a minimum, clinicians should document a clear period of stable
functioning before initiating medication taper and ensure that appropriate psychosocial
supports are in place to minimize relapse risk. No factors predicting relapse were identifiable
given the modest number of subjects in the discontinuation phase of this study, but they
certainly form an important future research question. Longer-term follow-up information on
outcome may help make decisions about maintenance treatment.
Although adverse events associated with risperidone exposure were observed to be common in
this study, most were not deemed clinically significant, and many were not attributed to
risperidone. No cases of dyskinesia were observed during treatment or upon withdrawal. The
absence of dyskinesia in this study may be noteworthy given the report by Campbell and
colleagues that 30% of 118 subjects showed dyskinesia following withdrawal of haloperidol
after a similar duration of treatment, although the more gradual taper used in this study may be
responsible for the finding. Weight gain associated with treatment was significant and some,
especially since antipsychotic-related weight gain has been associated with diabetes and other
adverse outcomes. Longer-term observations to determine the clinical significance of weight
gain as well as other adverse events are needed to evaluate the risk-benefit ratio for risperidone
treatment in children with autistic disorder.
There were several limitations in this investigation. First, although the data collection period in
this phase of the study spanned up to a maximum total of 8 weeks of risperidone exposure, this
does not completely mimic clinical practice, as many patients receive treatments like
risperidone for longer time periods. Also, there was no systematic effort to reduce or constrain
individual daily doses over time, leaving some uncertainty about the lowest possible long-term
dose. This limitation notwithstanding, the relatively low mean dose (approximately 2.0 mg/day)
of risperidone used in this study was effective in managing the specific target symptoms of
aggression, agitation, and self-injury. This mean dose was remarkably similar to the doses in
several other studies .The possibility of solidifying these gains or even extending the benefit of
risperidone treatment by combining it with behavior therapy was not explored in this
investigation but is an important research question for future studies. Finally, the safety
observations of the study were limited to a maximum of 8 weeks of risperidone exposure in a
relatively very small study group. Thus, our data may be insufficient to estimate precisely the
long-term risks of risperidone in children.
In summary, intermediate-length treatment with risperidone appeared to be associated with
the maintenance of reductions in aggression, agitation, self-injury, and irritability from short-
term treatment. There was little evidence of accommodation to the effects of risperidone, and
the medication appeared to be well tolerated in a group of children and adolescents with
autistic disorder. Additional studies on predictors of stable improvement, longer-term safety,
and approaches combining other interventions are of interest.
Conclusion:

13. Risperidone may be well-tolerated and may be effective at treating behavioral symptoms
associated with pervasive developmental disorders (PDD) and autism, according to the results
of a trial conducted on 4 children with confirmed diagnosis of PDD.
Risperidone can be beneficial in some features of autism. However there are limited data
available from our study with small sample size, limited inferences. In addition, long-term
follow-up is also lacking. Further research is necessary to determine the efficacy of risperidone
in clinical practice.
The main limitation of this study is the less number of children in control group and short
duration of follow up.
However it is concluded that the drug Risperidone is a beneficial drug for children in the Autism
spectrum disorder and more research on a large span of patients will produce more concrete
results towards reaching more effective handling of ASD.
References:
1. Chakrabarti S, Fombonne E: Pervasive developmental disorders in preschool children.
JAMA 2001; 285:3093–3099[Abstract/Free Full Text]
2. Rutter M, Silberg J, O’Connor T, Simonoff E: Genetics and child psychiatry, II: empirical
research findings. J Child Psychiatry 1999; 40:19–55
3. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J: The effects of
haloperidol on discrimination learning and behavioral symptoms in autistic children. J
Autism Dev Disord 1989; 19:227–239[CrossRef][Medline]
4. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R,
Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K,
Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B,
Ritz L, Davies M, Robinson J, McMahon D (Research Units on Pediatric
Psychopharmacology Autism Network): a double-blind, placebo-controlled trial of
risperidone in children with autistic disorder. N Engl J Med 2002; 347:314–
321[CrossRef][Medline]
5. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, Overall JE: Long-term
efficacy of haloperidol in autistic children: continuous versus discontinuous drug
administration. J Am Acad Child Adolesc Psychiatry 1989; 28:87–92[Medline]

14. 6. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ,
Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B,
Volkmar FR, Votolato NA, Walson P: Research Units on Pediatric Psychopharmacology
(RUPP) Autism Network: background and rationale for an initial controlled study of
risperidone. Child Adolesc Psychiatr Clin N Am 2000; 9:201–224[Medline]
7. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind,
placebo-controlled study of risperidone in adults with autistic disorder and other
pervasive developmental disorders. Arch Gen Psychiatry 1998; 55:633–
641[Abstract/Free Full Text]
8. Fisman S, Steele M: Use of risperidone in pervasive developmental disorders: a case
series. J Child Adolesc Psychopharmacol 1996; 6:177–190[Medline]
9. Scahill L, McCracken J, McDougle CJ, Aman M, Arnold LE, Tierney E, Cronin P, Davies M,
Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N,
Volkmar F, Ritz L, Vitiello B: Methodological issues in designing a multisite trial of
risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol
2001; 11:377–388[CrossRef][Medline]
10. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview—Revised: a revised version
of a diagnostic interview for caregivers of individuals with possible pervasive
developmental disorders. J Autism Dev Disord 1994; 24:659–685[CrossRef] Medline
11. Lord C, Pickles A, McLennan J, Rutter M, Bregman J, Folstein S, Fombonne E, Leboyer M,
Minshew N: Diagnosing autism: analyses of data from the Autism Diagnostic Interview. J
Autism Dev Disord 1997; 27:501–517[CrossRef][Medline]
12. Carter AS, Volkmar FR, Sparrow SS, Wang JJ, Lord C, Dawson G, Fombonne E, Loveland K,
Mesibov G, Schopler E: The Vineland Adaptive Behavior Scales: supplementary norms
for individuals with autism. J Autism Dev Disord 1998; 28:287–302[CrossRef][Medline]
13. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-
Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough
JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F: Assessment in multisite randomized
clinical trials of patients with autistic disorder: the Autism RUPP [Research Units on
Pediatric Psychopharmacology] Network. J Autism Dev Disord 2000; 30:99–111
14. Aman MG, Singh NN: Aberrant Behavior Checklist—Community: Supplementary Manual.
East Aurora, NY, Slosson Educational Publications, 1994
15. Brown EC, Aman MG, Havercamp SM: Factor analysis and norms for parent ratings on
the Aberrant Behavior Checklist—Community for young people in special education. Res
Dev Disabil 2002; 23:45–60[CrossRef][Medline]

15. 16. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76–
338. Washington, DC, US Department of Health, Education, and Welfare, 1976
17. Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M,
Hollway J, Aman MG, Cronin P, Koenig K, Kohn AE, McMahon DJ, Tierney E: Parent-
defined target symptoms respond to risperidone in RUPP Autism Network Study: a
customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42:1443–
1450[CrossRef][Medline]
18. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr
Scand Suppl 1970; 212:11–19[Medline]
19. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT,
Imber SD, Sotsky SM, Watkins JT: Some conceptual and statistical issues in analysis of
longitudinal psychiatric data: application to the NIMH Treatment of Depression
Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50:739–
750[Abstract/Free Full Text]
20. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ,
Tierney E, Chuang S, Vitiello B, Research Units on Pediatric Psychopharmacology Autism
Network: Weight and leptin changes among risperidone-treated youths with autism: 6-
month prospective data. Am J Psychiatry 2004; 161:1125–1127[Abstract/Free Full Text]
21. Zuddas A, Di Martino A, Muglia P, Cichetti C: Long-term risperidone for pervasive
developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc
Psychopharmacol 2000; 10:79–90[Medline]
22. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA: Risperidone treatment in
children and adolescents with autism: short- and long-term safety and effectiveness. J
Am Acad Child Adolesc Psychiatry 2002; 41:140–147[CrossRef][Medline]
23. Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children
with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001;
40:1206–1214[CrossRef][Medline]
24. Dartnall NA, Holmes JP, Morgan SN, McDougle CJ: Brief report: two-year control of
behavioral symptoms with risperidone in two profoundly retarded adults with autism. J
Autism Dev Disord 1999; 29:87–91[CrossRef]Medline
25. Pappadopulos E, Macintyre JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler
N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M,
Ketner S, Siennick SE, Jensen PS: Treatment recommendations for the use of
antipsychotics for aggressive youth (TRAAY), part II. J Am Acad Child Adolesc Psychiatry
2003; 42:145–161[CrossRef][Medline]

16. 26. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE:
Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J
Am Acad Child Adolesc Psychiatry 1997; 36:835–843[CrossRef][Medline]
27. Findling RL, Maxwell K, Wiznitzer M: An open clinical trial of risperidone monotherapy in
young children with autistic disorder. Psychopharmacol Bull 1997; 33:155–159[Medline]
28. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized controlled
trial of risperidone in the treatment of aggression in hospitalized adolescents with
subaverage cognitive abilities. J Clin Psychiatry 2001; 62:239–248[Medline]